218 related articles for article (PubMed ID: 16236069)
1. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
Fabbri A; Aversa A
Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
3. Centrally acting mechanisms for the treatment of male sexual dysfunction.
Miner MM; Seftel AD
Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic dilemma: how to use tadalafil.
Carosa E; Lombardo F; Martini P; Brandetti F; Jannini EA
Int J Androl; 2005 Dec; 28 Suppl 2():74-80. PubMed ID: 16236070
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
8. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
9. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Sussman DO
J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of testosterone in the treatment of erectile dysfunction.
Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 mechanisms and therapeutic applications.
Burnett AL
Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
Blonde L
Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
[TBL] [Abstract][Full Text] [Related]
15. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
16. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of erectile dysfunction in the primary care setting.
Rosenberg MT
Int J Clin Pract; 2007 Jul; 61(7):1198-208. PubMed ID: 17577299
[TBL] [Abstract][Full Text] [Related]
18. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
19. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
Ishii N; Nagao K; Fujikawa K; Tachibana T; Iwamoto Y; Kamidono S
Int J Urol; 2006 Aug; 13(8):1066-72. PubMed ID: 16903931
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
Francis SH; Morris GZ; Corbin JD
Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
